Pfizer Inc. $PFE Shares Bought by Naviter Wealth LLC

Naviter Wealth LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,958 shares of the biopharmaceutical company’s stock after acquiring an additional 685 shares during the period. Naviter Wealth LLC’s holdings in Pfizer were worth $1,308,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in PFE. Brighton Jones LLC grew its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Pfizer by 69.0% in the 1st quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock valued at $1,600,000 after buying an additional 25,785 shares during the period. Elevation Point Wealth Partners LLC boosted its holdings in shares of Pfizer by 15.9% in the 1st quarter. Elevation Point Wealth Partners LLC now owns 16,809 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 2,311 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Pfizer by 55.3% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,606,123 shares of the biopharmaceutical company’s stock valued at $66,039,000 after buying an additional 928,180 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.8%

PFE stock opened at $24.53 on Wednesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.82. The company has a market capitalization of $139.44 billion, a price-to-earnings ratio of 13.05, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The firm’s 50-day moving average is $24.88 and its two-hundred day moving average is $24.12. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm earned $0.60 EPS. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on PFE shares. Morgan Stanley decreased their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $28.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.